About 15 to 20% of breast cancers overexpresses human epidermal growth factor receptor-2 (HER2) [3] – a clinically important subtype of breast cancer that is associated with an aggressive disease phenotype and shortened survival outcomes [4], resulting in poorer prognosis compared to other subtypes. This evidence concerns the gene ERBB2 and breast cancer.